HCSE - internal use
|
|
|
|
|
|
300 mg HCSE caps. 2×/day (brand not stated) |
20 days |
R, DB, PC, PG, CO |
CVI, varicosis |
Significant alleviation (p < 0.05) of leg pain, oedema and pruritus in participants treated with HCSE compared to placebo
|
Neiss and Böhm (1976)Neiss, A., Böhm, C., 1976. Zum Wirksamkeitsnachweis von Roßkastaniensamenextrakt beim varikösen Symptomenkomplex. Munchen. Med. Wochen. 118, 213-216.
|
n = 226 |
300 mg HCSE caps. 2×/day (brand not stated) |
20 days |
R, DB, PC, CO |
CVI, varicosis |
Significant reduction (p < 0.05) of calf spasm, pain, fatigue, and tenseness compared to placebo
|
Friederich et al. (1978)Friederich, H.C., Vogelsberg, H., Neiss, A., 1978. Ein Beitrag zur Bewertung von intern wirksamen Venenpharmaka. Z. Hautkrankheiten. 53, 369-374.
|
n = 95 |
300 mg HCSE caps. 2×/day Venostasin® Retard |
8 weeks |
R, DB, PC, PG |
CVI |
Reduction of leg volume of 16.5 ml compared to 3.8 ml reduction with placebo, reduction of formation of oedema (21.0 ml) with HCSE and increase (0.2 ml) with placebo during oedema-provoking period |
Lohr et al. (1986)Lohr, E., Garanin, G., Jesau, P., Fischer, H., 1986. Ödempräventive Therapie bei chronischer Veneninsuffizienz mit Ödemneigung. Munchen. Med. Wochen. 128, 579-581.
|
n = 74 |
2 × 300 mg HCSE caps. 1×/day Venostasin® Retard |
4 weeks |
R, DB, PC, CO |
CVI |
Significant reductions (p < 0.01) of capillary filtration coefficient by 22% compared to placebo
|
Bisler et al. (1986)Bisler, H., Pfeifer, R., Klüken, N., Pauschinger, P., 1986. Wirkung von Roßkastaniensamenextrakt auf die transkapilläre Filtration bei chronisch venöser Insuffizienz. Deut. Med. Wochenschr. 111, 1321-1399.
|
n = 22 |
300 mg HCSE caps. 2×/day (brand not stated) |
4 weeks |
R, DB, PC, PG |
CVI grade I or II |
Significant reduction (p < 0.001) in leg volume (78 ml) compared to increase with placebo (34 ml), significant reduction (p < 0.01) in calf and foot circumference, significant reduction in subjective parameters (pain, tiredness, tension, and pruritus in legs) compared to placebo |
Rudofsky et al. (1986)Rudofsky, G., Neiss, A., Otto, K., Seibel, K., 1986. Ödemprotektive Wirkung und klinische Wirksamkeit von Roßkastaniensamenextrakt im Doppeltblindversuch. Phlebol. Proktol. 15, 47-54.
|
n = 39 |
300 mg HCSE caps. 2×/day (brand not stated) |
20 days |
R, DB, PC, PG |
CVI |
Significant reduction (p < 0.05) of 0.8 cm in leg circumference and oedema at ankle compared with placebo, alleviation of subjective symptoms (p < 0.05) |
Pilz (1990)Pilz, E., 1990. Ödeme bei Venenerkrankungen. Med. Welt 41, 1143-1144.
|
n = 28 |
300 mg HCSE caps. 2×/day Venostasin® Retard |
20 days |
R, DB, PC, CO |
Pregnant women with oedema due to CVI |
Significant reduction (p < 0.01) in foot volume before and after oedema provocation and greater resistance to oedema provocation compared to placebo, reduction in foot circumference and subjective symptoms compared to placebo
|
Steiner and Hillemanns (1990)Steiner, M., Hillemanns, H.G., 1990. Venostasin retard in the management of venous problems during pregnancy. Phlebology 5, 41-44.
|
n = 52 |
300 mg HCSE caps. 2×/day Venostasin® Retard |
2 weeks |
R, DB, PC, CO |
CVI, varicosis during pregnancy |
Significant reduction (p = 0.009) in leg volume (114 ml in patients with varicose veins and 126 ml in patients with CVI) and subjective symptoms (p < 0.05) compared to placebo
|
Steiner (1991)Steiner, M., 1991. Ausmaß der ödemprotektiven Wirkung von Roßkastaniensamenextrakt. VASA 20(Suppl. 33), 217.
|
n = 20 |
3 00 mg HCSE caps. 2×/day (brand not stated) |
6 weeks |
R, DB, PC, PG |
Venous oedema in chronic deep vein incompetence (CVI grade II) |
Significant reduction (p < 0.01) in leg volume by an average of 84 ml compared with baseline, while reduction of 4 ml with placebo, alleviation of subjective symptoms (feelings of heaviness, tension, fatigue, and paresthesia) in legs, itching not helped |
Diehm et al. (1992)Diehm, C., Vollbrecht, D., Amendt, K., Comberg, H.U., 1992. Medical edema protection – clinical benefit in patients with chronic deep vein incompetence. VASA 21, 188-192.
|
n = 39 |
|
|
|
|
|
|
HCSE - external use
|
|
|
|
|
|
Esseven gel |
4 weeks |
R |
SVT |
Alleviation of subjective symptoms, decrease in body temperature |
De Sanctis et al. (2001)De Sanctis, M.T., Cesarone, M.R., Incandela, L., Belcaro, G., Griffin, M., 2001. Treatment of superficial vein thrombosis with standardized application of Essaven gel – a placebo-controlled, randomized study. Angiology 52(Suppl. 3), 57-62.
|
n = 30 |
Esseven gel 1×/day |
4 weeks |
R |
CVI, acute lower leg ulcers |
Improved blood flow parameters and microcirculation, alleviation of subjective symptoms |
Cesarone et al. (2001a)Cesarone, M.R., Incandela, L., Belcaro, G., De Sanctis, M.T., Ricci, A., Griffin, M., 2001a. Two-week topical treatment with Essaven gel in patients with diabetic microangiopathy – a placebo-controlled, randomized study. Angiology 52(Suppl. 3), 43-48.
|
n = 22 |
Esseven gel |
4 weeks |
R, DB |
Foot ulcers as a result of diabetes complications |
Improvement of microcirculation, reduction of skin ulcers |
Cesarone et al. (2001b)Cesarone, M.R., De Sanctis, M.T., Incandela, L., Belcaro, G., Griffin, M., 2001b. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel – a placebo-controlled, randomized study. Angiology 52(Suppl. 3), 11-16. and Incandela et al. (2001)Incandela, L., Belcaro, G., Nicolaides, A.N., Geroulakos, G., Cesarone, M.R., De Sanctis, M.T., 2001. Microcirculation after standardized application of Essaven gel on normal skin – a placebo-controlled, randomized study. Angiology 52(Suppl. 3), 5-10.
|
n = 15 |
|
|
|
|
|
|
HCSE vs. reference medications
|
|
|
|
|
|
300 mg HCSE caps. 2×/day vs. reference medication (probably rutosides, brand not stated) |
4 weeks |
R, DB, PG, Cm n = 30 |
CVI |
Significantly reduced (p value not reported) ankle circumference by 0.4 cm and improved subjective symptoms compared with baseline, ankle circumference reduced by 0.4 cm (rutosides) |
Erdlen (1989)Erdlen, F., 1989. Klinische Wirksamkeit von Venostasin retard im Doppelblindversuch. Med. Welt. 40, 994-996.
|
300 mg HCSE caps. 1×/day vs. 500 mg HR 1×/day (brand not stated) |
8 weeks |
R, DB, PG, Cm n = 30 |
CVI |
Ankle and calf circumference reduced by 0.2 and 0.18 cm, respectively, compared to baseline, values not significantly different compared with HR |
Kalbfleisch and Pfalzgraf (1989)Kalbfleisch, W., Pfalzgraf, H., 1989. Ödemprotektiva Äquipotente Dosierung – Roßkastaniensamenextrakt und O-β-Hydroxyethylrutoside im Vergleich. Therapiewoche 39, 3703-3707.
|
300 mg HCSE caps. 2×/day vs.2000 mg HR 1×/day |
8 weeks |
R, DB, PG, Cm n = 40 |
CVI and peripheral venous oedema |
HCSE significantly protected calf and ankle from oedema provocation compared with baseline, both HCSE and HR comparable in reducing oedema, more pronounced protective effect of HCSE |
Erler (1991)Erler, M., 1991. Roßkastaniensamenextrakt bei der Therapie peripherer venöser Ödeme – ein klinischer Therapievergleich. Med. Welt 42, 593-596.
|
300 mg HCSE caps. 2×/day vs. 1000 mg HR3/day (4 weeks) 500 mg HR3/day (4 weeks) (brand not stated) |
12 weeks |
R, DB, PG, MC, Cm n = 137 |
Postmenopausal CVI grade II |
Significant reduction (p value not reported) in leg volume of 28 ml (HCSE), 58 ml (HR 1000 mg/day) and 40 ml (HR 1000 mg/day for 4 weeks then 500 mg/day for 8 weeks) compared to baseline, alleviated subjective symptoms, after 6-week follow-up period both treatments exhibited substantial carry-over effect |
Rehn et al. (1996)Rehn, D., Unkauf, M., Klein, P., Jost, V., Lücker, P.W., 1996. Vergleich der klinischen wirksamkeit und vertraglichkeit von oxerutin und Rosskastanien – extract bei patienten mit chronischer venoser Insuffizienz. Arzneimittel-Forsch. 46, 483-487.
|
300 mg HCSE caps. 2×/day (Venostasin® Retard) vs.mechanical compression with bandages and class II elastic stocking |
12 weeks |
R, SB, PC, PG, Cm n = 240 |
CVI |
Significant reduction in leg volume of 43.8 ml (HCSE), 46.7 ml (compression therapy) and increase -9.8 ml (placebo) (HCSE and compression therapy vs. placebo p = 0.005), HCSE compared with compression therapy p = 0.001), HSCE was well-tolerated (98% compliance), whereas compression treatment was reported as uncomfortable, inconvenient and subject to poor (90%) compliance |
Diehm et al. (1996)Diehm, C., Trampish, H.J., Lange, S., Schmidt, C., 1996. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 347, 292-294.
|
300 mg HCSE caps. 2×/day (Venostasin® Retard) vs.mechanical compression with bandages and class II elastic stocking |
16 weeks |
R, DB, PC, PG, Cm n = 286 |
CVI grade II and IIIa |
Reduction of lower leg volume during treatment in both therapy groups, whereas in placebo group, there were no effects |
Diehm and Schmidt (2001)Diehm, C., Schmidt, C., 2001. Venostasin retard gegen Plazebo und Kompression bei Patienten mit CVI II/IIIA. Final Study Report. Klinge Pharma GmbH Munich, Germany. Reported in: Ottillinger B et al. BMC Cardiovasc. Disord. 1, 5.
|
300 mg HCSE caps. 2×/day (Venostasin® Retard) vs. 360 mg Pycnogenol/day |
4 weeks |
R, PG, O, Cm n = 40 |
CVI |
Pycnogenol: significant reduction of circumference of lower limbs, significantly improved subjective symptoms of pain, cramps, night-time swelling, feeling of 'heaviness', and reddening of skin, decrease in cholesterol and LDL values in blood, whereas HDL remained unaffected, Venostasin: insignificant reduction of circumference of lower limbs, marginally improved symptoms, no influence on the determined lipid values, both medications were equally well tolerated |
Koch (2002)Koch, R., 2002. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother. Res. 16(Suppl. 1), 1-5.
|